Saccharomyces boulardii for the Prevention of Antibiotic-Associated Diarrhea in Adult Hospitalized Patients: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Trial

2012 ◽  
Vol 107 (6) ◽  
pp. 922-931 ◽  
Author(s):  
Pietro Pozzoni ◽  
Alessia Riva ◽  
Alessandro Giacco Bellatorre ◽  
Maria Amigoni ◽  
Elena Redaelli ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Saccharomyces Boulardii ◽  
Hospitalized Patients ◽  
Single Center ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Antibiotic Associated Diarrhea

scholarly journals Effect of a Fermented Milk CombiningLactobacillus AcidophilusCL1285 andLactobacillus Caseiin the Prevention of Antibiotic-Associated Diarrhea: A Randomized, Double-Blind, Placebo-Controlled Trial

2007 ◽  
Vol 21 (11) ◽  
pp. 732-736 ◽  
Author(s):  
Mélanie Beausoleil ◽  
Nadia Fortier ◽  
Stéphanie Guénette ◽  
Amélie L’Ecuyer ◽  
Michel Savoie ◽  
...  
Keyword(s):  
Placebo Group ◽  
Controlled Trial ◽  
Randomized Study ◽  
Fermented Milk ◽  
Daily Basis ◽  
Hospitalized Patients ◽  
Double Blind ◽  
Antibiotic Associated Diarrhea ◽  
Potential Measure ◽  
To Receive

BACKGROUND: Antibiotic-associated diarrhea is an important problem in hospitalized patients. The use of probiotics is gaining interest in the scientific community as a potential measure to prevent this complication. The main objective of the present study was to assess the efficacy and safety of a fermented milk combiningLactobacillus acidophilusandLactobacillus caseithat is widely available in Canada, in the prevention of antibiotic-associated diarrhea.METHODS: In this double-blind, randomized study, hospitalized patients were randomly assigned to receive either a lactobacilli-fermented milk or a placebo on a daily basis.RESULTS: Among 89 randomized patients, antibiotic-associated diarrhea occurred in seven of 44 patients (15.9%) in the lactobacilli group and in 16 of 45 patients (35.6%) in the placebo group (OR 0.34, 95% CI 0.125 to 0.944; P=0.05). The median hospitalization duration was eight days in the lactobacilli group, compared with 10 days in the placebo group (P=0.09). Overall, the lactobacilli-fermented milk was well tolerated.CONCLUSION: The daily administration of a lactobacilli-fermented milk was safe and effective in the prevention of antibiotic-associated diarrhea in hospitalized patients.

Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis

2012 ◽  
Vol 18 (5) ◽  
pp. 803-808 ◽  
Author(s):  
Haruhiko Ogata ◽  
Jun Kato ◽  
Fumihito Hirai ◽  
Nobuyuki Hida ◽  
Toshiyuki Matsui ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Controlled Trial ◽  
Hospitalized Patients ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Steroid Refractory

scholarly journals A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Saccharomyces boulardii in Infants and Children With Acute Diarrhea

2020 ◽  
Vol 39 (11) ◽  
pp. e347-e351
Author(s):  
Florian Mourey ◽  
Varun Sureja ◽  
Dharmeshkumar Kheni ◽  
Parthiv Shah ◽  
Devang Parikh ◽  
...  
Keyword(s):  
Acute Diarrhea ◽  
Controlled Trial ◽  
Saccharomyces Boulardii ◽  
Infants And Children ◽  
Double Blind ◽  
Double Blind Placebo ◽  
In Infants And Children

scholarly journals NITRATE-CIN Study: Protocol of a Randomized (1:1) Single-Center, UK, Double-Blind Placebo-Controlled Trial Testing the Effect of Inorganic Nitrate on Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography for Acute Coronary Syndromes

2021 ◽  
pp. 107424842100052
Author(s):  
Anne-Marie Beirne ◽  
Oliver Mitchelmore ◽  
Susana Palma ◽  
Mervyn Andiapen ◽  
Krishnaraj S. Rathod ◽  
...  
Keyword(s):  
Acute Coronary Syndromes ◽  
Controlled Trial ◽  
Single Center ◽  
Contrast Induced Nephropathy ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Inorganic Nitrate ◽  
Nitrate Therapy ◽  
Risk Patients ◽  
Coronary Syndromes

Background: Contrast-induced nephropathy (CIN), an acute kidney injury resulting from the administration of intravascular iodinated contrast media, is a significant cause of morbidity/mortality following coronary angiographic procedures in high-risk patients. Despite preventative measures intended to mitigate the risk of CIN, there remains a need for novel effective treatments. Evidence suggests that delivery of nitric oxide (NO) through chemical reduction of inorganic nitrate to NO may offer a novel therapeutic strategy to reduce CIN and thus preserve long term renal function. Design: The NITRATE-CIN trial is a single-center, randomized, double-blind placebo-controlled trial, which plans to recruit 640 patients presenting with acute coronary syndromes (ACS) who are at risk of CIN. Patients will be randomized to either inorganic nitrate therapy (capsules containing 12 mmol KNO3) or placebo capsules containing potassium chloride (KCl) daily for 5 days. The primary endpoint is development of CIN using the Kidney Disease Improving Global Outcomes (KDIGO) criteria. A key secondary endpoint is renal function over a 3-month follow-up period. Additional secondary endpoints include serum renal biomarkers (e.g. neutrophil gelatinase-associated lipocalin) at 6 h, 48 h and 3 months following administration of contrast. Cost-effectiveness of inorganic nitrate therapy will also be evaluated. Summary: This study is designed to investigate the hypothesis that inorganic nitrate treatment decreases the rate of CIN as part of semi-emergent coronary angiography for ACS. Inorganic nitrate is a simple and easy to administer intervention that may prove useful in prevention of CIN in at-risk patients undergoing coronary angiographic procedures.

scholarly journals Effect of Coenzyme Q10 on Insulin Resistance in Korean Patients with Prediabetes: A Pilot Single-Center, Randomized, Double-Blind, Placebo-Controlled Study

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Ja-Young Yoo ◽  
Keun-Sang Yum
Keyword(s):  
Insulin Resistance ◽  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Coenzyme Q10 ◽  
Controlled Trial ◽  
Controlled Study ◽  
Model Assessment ◽  
Single Center ◽  
Double Blind ◽  
Double Blind Placebo

Introduction. This study aimed to examine whether administration of coenzyme Q10, an antioxidant, improves insulin resistance in patients with prediabetes. The study design was a pilot single-center, randomized, double-blind, placebo-controlled trial. Methods. This pilot single-center, randomized, double-blind, placebo-controlled trial included a total of 80 adults (aged ≥20 years) with impaired glucose tolerance. After the initial screening visit, subjects were assigned to either the experimental (n = 40) or placebo (n = 40) group via simple randomization. Insulin resistance was represented as the insulin resistance index estimated by homeostasis model assessment (HOMA-IR). Results. After the 8-week treatment period, the coenzyme group exhibited a significant decrease in the HOMA-IR (P < .001). The free oxygen radical and coenzyme Q10 concentrations were found to correlate significantly (P < .001). However, no significant changes in fasting blood glucose, insulin, and glycated hemoglobin levels were observed in either group. Additionally, no adverse events occurred in either group. Conclusion. Patients with prediabetes who were administered coenzyme Q10 showed a significant reduction in HOMA-IR values. Therefore, administration of coenzyme Q10 in patients with impaired glucose tolerance may slow the progression from prediabetes to overt diabetes.

scholarly journals Treatment with L-Citrulline in patients with post-polio syndrome: A single center, randomized, double blind, placebo-controlled trial

2021 ◽  
Author(s):  
Niveditha Putananickal ◽  
Anna-Lena Orsini ◽  
Simone Schmidt ◽  
Vanya Gocheva ◽  
Daniela Rubino ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Single Center ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document